Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition

被引:1
|
作者
Yang, XW
Ferguson, AT
Nass, SJ
Phillips, DL
Butash, KA
Wang, SM
Herman, JG
Davidson, NE
机构
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA
[2] Univ Chicago, Med Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent findings have established a connection between DNA methylation and transcriptionally inactive chromatin characterized by deacetylated histones, Because the absence of estrogen receptor alpha (ER alpha) gene expression has been associated with aberrant methylation of its CpG island in a significant fraction of breast cancers, we tested whether histone deacetylase activity contributes to the transcriptional inactivation of the methylated ER gene in a panel of ER-negative human breast cancer cells. Treatment of these cells with trichostatin A, a specific histone deacetylase inhibitor, led to dose- and time-dependent re-expression of ER mRNA as detected by reverse transcription-PCR without alteration in ER alpha CpG island methylation. Trichostatin A-induced ER re-expression was associated with increased sensitivity to DNase I at the ER locus in MDA-MB-231 cells. These data implicate inactive chromatin mediated by histone deacetylation as a critical component of ER gene silencing in human breast cancer cells. Therefore, histone deacetylation may be a potential target for therapeutic intervention in the treatment of a subset of ER-negative breast cancers.
引用
收藏
页码:6890 / 6894
页数:5
相关论文
共 50 条
  • [41] Histone deacetylase inhibitors as differentiation agents in breast cancer cells
    Ismail, H.
    Bail, M.
    Laperriere, D.
    Mader, S.
    FEBS JOURNAL, 2014, 281 : 303 - 303
  • [42] Troglitazone inhibits histone deacetylase activity in breast cancer cells
    Davies, G. F.
    Ross, A. R.
    Arnason, T. G.
    Juurlink, B. H. J.
    Harkness, T. A. A.
    CANCER LETTERS, 2010, 288 (02) : 236 - 250
  • [43] Histone deacetylase inhibition in ovarian cancer
    Wine, I. S.
    Tan, L.
    Kwok, R.
    Opipari, A. W.
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S35 - S36
  • [44] Histone deacetylase inhibitors as differentiation agents in breast cancer cells
    Ismail, Houssam
    Bail, Martine
    LaperriSre, David
    Hilmi, Khalid
    Mader, Sylvie
    CANCER RESEARCH, 2013, 73
  • [45] The role of 14-3-3β in transcriptional activation of estrogen receptor α and its involvement in proliferation of breast cancer cells
    Kim, Yoonseo
    Kim, Hyungjin
    Jang, Sung-Wuk
    Ko, Jesang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 414 (01) : 199 - 204
  • [46] Inhibition of histone deacetylase 6 sensitizes human leukemia and breast cancer cells to inhibitor of heat shock protein 90 and/or bortezomib
    Bali, Purva
    Balasis, Maria
    Fiskus, Warren
    Pranpat, Michael
    Rocha, Kathy
    Kumaraswamy, Sandhya
    Boyapalle, Sandhya
    Atadja, Peter
    Bhalla, Kapil
    CANCER RESEARCH, 2006, 66 (08)
  • [47] A histone deacetylase inhibitor potentiates estrogen receptor activation of a stably integrated vitellogenin promoter in HepG2 cells
    Mao, CJ
    Shapiro, DJ
    ENDOCRINOLOGY, 2000, 141 (07) : 2361 - 2369
  • [48] Restoration of transforming growth factor-β signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells
    Ammanamanchi, S
    Brattain, MG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (31) : 32620 - 32625
  • [49] Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors
    Zou, Zhengzhi
    Luo, Xiaoyong
    Nie, Peipei
    Wu, Baoyan
    Zhang, Tao
    Wei, Yanchun
    Wang, Wenyi
    Geng, Guojun
    Jiang, Jie
    Mi, Yanjun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 478 (01) : 227 - 233
  • [50] Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
    Vuletic, Ana
    Martinovic, Katarina Mirjacic
    Spasic, Jelena
    PHARMACEUTICS, 2024, 16 (01)